USPSTF Recognizes Epi proColon as the Only Blood-Based Colorectal Cancer Screening Test
Complete the form below to unlock access to ALL audio articles.
Epigenomics AG has announced that the United States Preventive Task Force (USPSTF) has included Epi proColon® in its new recommendation statement for colorectal cancer screening, published in the Journal of the American Medical Association (JAMA). USPSTF is the first U.S. guideline body to recognize this novel colorectal cancer screening test after its recent FDA approval.
In its statement, the USPSTF highlights that there is convincing evidence that colorectal cancer screening substantially reduces deaths from the disease and that not enough people in the United States are using screening tests.
In the recommendation, the USPSTF names Epi proColon (“SEPT9 DNA test”) as one of several screening tests for the detection of early-stage colorectal cancer. The use of screening tests such as Epi proColon is recommended in the population of adults between 50 to 75 years.
The USPSTF also acknowledges that there is no “one size fits all” approach to colorectal cancer screening. As a consequence, instead of emphasizing specific screening approaches, the new guideline rather focuses on the importance of patient participation in CRC screening, without recommending for or against any particular method. However, only methods with substantial scientific evidence were included in their review of available tests.
Epigenomics expects that the new USPSTF recommendation will contribute to higher CRC screening rates, which have been stagnant over the past years. The American Cancer Society and other medical guideline bodies pursue a colorectal cancer screening goal of 80% of eligible patients.
“We are excited about the inclusion of Epi proColon in the new USPSTF recommendation, which recognizes the potential role of our novel blood-based test in colorectal cancer screening, especially in driving patient compliance in individuals who are reluctant to collect stool samples or undergo colonoscopy” said Dr. Thomas Taapken, CEO/CFO of Epigenomics AG. “This recommendation emphasizes the need for additional screening options and will help to drive medical adoption and support reimbursement coverage of Epi proColon in U.S. market.”
